Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page

    Convalescent plasma for preventing critical illness in COVID-19 MESHD: A phase 2 trial and immune profile

    Authors: Jeffrey Michael Sturek; Tania A Thomas; James D Gorham; Chelsea A Sheppard; Allison E Raymond; Kristen Petros De Guex; William B Harrington; Andrew J Barros; Gregory R Madden; Yosra M Alkabab; David Lu; Qin Liu; Melinda D Poulter; Amy J Mathers; Archana Thakur; Ewa M Kubicka; Lawrence G Lum; Scott K Heysell

    doi:10.1101/2021.02.16.21251849 Date: 2021-02-19 Source: medRxiv

    RationaleThe COVID-19 pandemic MESHD caused by the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is an unprecedented event requiring rapid adaptation to changing clinical circumstances. Convalescent immune plasma ( CIP MESHD CIP HGNC) is a promising treatment that can be mobilized rapidly in a pandemic setting. ObjectivesWe tested whether administration of SARS-CoV-2 CIP MESHD CIP HGNC at hospital admission could reduce the rate of ICU transfer or 28 day mortality. MethodsIn a single-arm phase II study, patients >18 years-old with respiratory symptoms documented with COVID-19 MESHD infection who were admitted to a non-ICU bed were administered two units of CIP HGNC within 72 hours of admission. Detection of respiratory tract SARS-CoV-2 by polymerase chain reaction and circulating anti-SARS-CoV-2 antibody titers were measured before and at time points after CIP HGNC transfusion. Measurements and Main ResultsTwenty-nine patients were transfused CIP HGNC and forty-eight contemporaneous controls were identified with comparable baseline characteristics. Levels of anti-SARS-CoV-2 IgG, IgM, and IgA anti-spike, anti-receptor-binding domain, and anti-nucleocapsid significantly increased from baseline to post-transfusion for all proteins tested. In patients transfused with CIP HGNC, the rate of ICU transfer was 13.8% compared to 27.1% for controls with a hazard ratio 0.506 (95% CI 0.165-1.554), and 28-day mortality was 6.9% compared to 10.4% for controls, hazard ratio 0.640 (95% CI 0.124-3.298). ConclusionsTransfusion of high-titer CIP MESHD CIP HGNC to patients early after admission with COVID-19 MESHD respiratory disease MESHD was associated with reduced ICU transfer and 28-day mortality but was not statistically significant. Follow up randomized trials may inform the use of CIP HGNC for COVID-19 MESHD or future coronavirus pandemics.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.